Spero Therapeutics
Cambridge, United States (US) · Science and Engineering
Do your work at Spero Therapeutics?
Claim this profile to manage your company.
Verified by Enterprise League
Data quality
Complete · Accuracy
Last verified
Apr 2026
Overview
We are a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant ("MDR”) bacterial infections with high unmet need. Our pipeline consists of three mid to late-stage clinical assets. Tebipenem HBr is in Phase 3 development, with the potential to be the first broad-spectrum oral carbapenem to treat complicated urinary tract infections ("cUTIs”) including acute pyelonephritis, caused by certain microorganisms, in adult patients. SPR206 is a Phase 2 ready IV-administered antibiotic being developed as an innovative option to treat MDR Gram-negative bacterial infections in the hospital setting. SPR720, the development of which was recently suspended, is a Phase 2 investigational oral agent for the first-line treatment of nontuberculous mycobacterial ("NTM”) pulmonary disease, a rare disease. As previously disclosed, following the SPR720 program suspension, we are evaluating other potential paths forward as the remaining data are collected and analyzed.
Contact Details
info@sperotherapeutics.com
Cambridge, United States (US)
Founded
2013
Employees
20-30
Categories
Keywords
#Antibacterial Therapies
#Novel Therapeutics
#Infectious Disease
Companies teams usually look at after Spero Therapeutics
Comparing a few options usually leads to better decisions
Save companies to compare later. Useful when sharing options with your team
This is how your company profile looks to others.